Immuron (IMRN) Debt to Equity (2017 - 2020)

Immuron (IMRN) recorded quarterly Debt to Equity of $0.01 in Q2 2020, up 298.38% quarter-over-quarter from $0.0 in Q2 2019, and up 298.38% on a YoY basis from $0.0 in Q3 2019.

Immuron (IMRN) Debt to Equity (2017 - 2020) Analysis & Trends

Immuron's Debt to Equity history runs 3 years deep, the most recent figure standing at $0.01 for Q2 2020.

  • In Q2 2020, Debt to Equity rose 298.38% year-over-year to $0.01; the TTM figure through Jun 2020 stood at $0.01 (up 298.38% YoY), while the FY2020 annual figure was $0.01, up 298.38% from the prior year.
  • Debt to Equity was $0.01 for Q2 2020 at Immuron, up from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.02 in Q2 2017 to a low of $0.0 in Q2 2019.
  • Historically, Debt to Equity has averaged $0.01 across 3 years, with a median of $0.01 in 2020.
  • Biggest YoY gain for Debt to Equity was 298.38% in 2020; the steepest drop was 298.38% in 2020.
  • A 3-year view of Debt to Equity shows it stood at $0.02 in 2017, then tumbled by 91.27% to $0.0 in 2019, then soared by 298.38% to $0.01 in 2020.
  • The last three Debt to Equity figures came in at $0.01 (Q2 2020), $0.0 (Q2 2019), and $0.02 (Q2 2017), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.32
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Immuron 921.61 Mn 921.58 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2020 0.01
Jun 30, 2019 0.00
Jun 30, 2017 0.02